Matches in Nanopublications for { ?s ?p "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP372265.RAYFp1P9TUQwdhLHf7w-bZXVNtHteqkhsxDC91EDurHJw130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP372265.RAYFp1P9TUQwdhLHf7w-bZXVNtHteqkhsxDC91EDurHJw130_provenance.
- NP372361.RAbiVFW7kwno9Taf4aQT1x5lpfO8KAAz6itcKb9nXNKaY130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP372361.RAbiVFW7kwno9Taf4aQT1x5lpfO8KAAz6itcKb9nXNKaY130_provenance.
- NP675758.RAayXKG4-PSySDzZcoeXJ_9fbDhZb9zkfdC2cuRd2-oGI130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675758.RAayXKG4-PSySDzZcoeXJ_9fbDhZb9zkfdC2cuRd2-oGI130_provenance.
- assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1119970.RAZ-hbqlAgzM4Hd7dH17bIaoEM6c2A_JYjdMR6r2_-2rU130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1119970.RAZ-hbqlAgzM4Hd7dH17bIaoEM6c2A_JYjdMR6r2_-2rU130_provenance.
- NP675769.RADlfmOg96RX7qPppnIBMnheZjKbwUQer3wzbcb1WQfbc130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675769.RADlfmOg96RX7qPppnIBMnheZjKbwUQer3wzbcb1WQfbc130_provenance.
- NP1119969.RANQgwcLWWmX9_-9_XibdvVNyDJ6IOYfGYdNRrvLjs1FA130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1119969.RANQgwcLWWmX9_-9_XibdvVNyDJ6IOYfGYdNRrvLjs1FA130_provenance.
- NP1119975.RAPZv2e4YnuLCjZdhPJxGeCc4PF9JGXErUIu0JBaQvH8Q130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1119975.RAPZv2e4YnuLCjZdhPJxGeCc4PF9JGXErUIu0JBaQvH8Q130_provenance.
- NP1119972.RA1MX_51UMa-pzEDnNgj3l7_HD8XCm9wXUezpbaOlDRKQ130_assertion description "[The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1119972.RA1MX_51UMa-pzEDnNgj3l7_HD8XCm9wXUezpbaOlDRKQ130_provenance.